Bendamustine (Levact®) Plus Rituximab Doubles Progression-Free Survival in Patients with Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Compared with CHOP-R
Everyone's Blog Posts - Onco'Zine,
Results from the StiL NHL-1 study published in The Lancet earlier today show that a first-line treatment regimen of…